109 related articles for article (PubMed ID: 1466959)
1. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
Bona C; Nixon A; Kennedy R; Zaghouani H
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1377. PubMed ID: 1466959
[No Abstract] [Full Text] [Related]
2. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
Nixon A; Zaghouani H; Penney CL; Lacroix M; Dionne G; Anderson SA; Kennedy RC; Bona CA
Viral Immunol; 1992; 5(2):141-50. PubMed ID: 1616585
[TBL] [Abstract][Full Text] [Related]
3. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824
[TBL] [Abstract][Full Text] [Related]
4. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
[TBL] [Abstract][Full Text] [Related]
5. Production in rabbits of high levels of anti-HIV-1 gp160 antibodies.
Relyveld E; Bizzini B
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):389-93. PubMed ID: 7580832
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
[TBL] [Abstract][Full Text] [Related]
7. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
[TBL] [Abstract][Full Text] [Related]
8. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
9. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
Klaniecki J; Dykers T; Travis B; Schmitt R; Wain M; Watson A; Sridhar P; McClure J; Morein B; Ulrich JT
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):791-8. PubMed ID: 1742074
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
Barrett N; Eder G; Dorner F
Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
13. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory.
Mannhalter JW; Pum M; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
AIDS Res Hum Retroviruses; 1991 May; 7(5):485-93. PubMed ID: 1714748
[TBL] [Abstract][Full Text] [Related]
14. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.
Akerblom L; Nara P; Dunlop N; Morein B
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464
[TBL] [Abstract][Full Text] [Related]
15. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
Parry C; McLain L; Dimmock NJ
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
[TBL] [Abstract][Full Text] [Related]
16. Current approaches to vaccination against human immunodeficiency viruses.
Gluckman JC; Yagello M; Bahraoui E; Girard M
Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
[No Abstract] [Full Text] [Related]
17. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
18. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
[TBL] [Abstract][Full Text] [Related]
19. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates.
Hosmalin A; Nara PL; Zweig M; Lerche NW; Cease KB; Gard EA; Markham PD; Putney SD; Daniel MD; Desrosiers RC
J Immunol; 1991 Mar; 146(5):1667-73. PubMed ID: 1704401
[TBL] [Abstract][Full Text] [Related]
20. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
